This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BNOX Bionomics (BNOX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Bionomics Stock (NASDAQ:BNOX) 30 days 90 days 365 days Advanced Chart Get Bionomics alerts:Sign Up Key Stats Today's Range$0.24▼$0.2950-Day Range$0.24▼$0.3252-Week Range$0.18▼$0.94Volume7.43 million shsAverage Volume5.97 million shsMarket Capitalization$4.47 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company Overview Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia. Read More Receive BNOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Email Address BNOX Stock News HeadlinesBionomics Ltd – ADR trading halted, news pendingDecember 24, 2024 | markets.businessinsider.comBionomics Limited Receives Court Approval for Re-Domiciliation Scheme to Neuphoria Therapeutics Inc.December 18, 2024 | nasdaq.comMissed the Run So Far? This Is Your Second ChanceAccording to history, the final stretch of the crypto cycle is here — and this short window is where fortunes are made. Inside The Crypto Code Workshop, two experts reveal how to get positioned early, lock in profits, and access their top altcoin picks before the crowd. All attendees receive $10 in free Bitcoin just for showing up.July 18 at 2:00 AM | Crypto Swap Profits (Ad)Bionomics Ltd: Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-DomiciliationDecember 18, 2024 | finanznachrichten.deBionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-DomiciliationDecember 16, 2024 | globenewswire.comBionomics Ltd: Results of Scheme MeetingDecember 14, 2024 | finanznachrichten.deResults of Scheme MeetingDecember 12, 2024 | globenewswire.comBionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM EvidenceDecember 9, 2024 | markets.businessinsider.comSee More Headlines BNOX Stock Analysis - Frequently Asked Questions When did Bionomics IPO? Bionomics (BNOX) raised $20 million in an IPO on Thursday, December 16th 2021. The company issued 1,622,000 shares at a price of $12.35 per share. What other stocks do shareholders of Bionomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bionomics investors own include Meta Platforms (META), PayPal (PYPL), Intel (INTC), ChargePoint (CHPT), CRISPR Therapeutics (CRSP) and NVIDIA (NVDA). Company Calendar Today7/18/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BNOX CIK1191070 Webwww.bionomics.com.au Phone088-150-7400FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Bionomics$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+3,060.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.30 Quick Ratio3.30 Sales & Book Value Annual Sales$10 thousand Price / Sales446.82 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book0.19Miscellaneous Outstanding Shares17,654,000Free Float17,532,000Market Cap$4.47 million OptionableNot Optionable Beta0.26 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:BNOX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bionomics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bionomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.